[ad_1]
Take heed to this text
Johnson & Johnson (J&J) has had a “momentary setback” with its Ottava surgical robotic system. Talking on the corporate’s third-quarter earnings name, EVP Joseph Wolk mentioned that whereas the corporate maintains its dedication to growing a basic surgical procedure providing with Ottava, the platform’s growth timeline has been pushed again about two years attributable to a number of components.
The preliminary expectation was to start the verification and validation processes for Ottava in 2021, adopted by enrollment in medical trials for the machine in 2022.
“We recorded a partial in-process R&D cost for $900 million within the third quarter,” Wolk mentioned. “The accounting for this cost contemplates a first-in-human delay of roughly two years from our earlier projections of the second half of 2022, reflecting technical growth challenges and COVID-19-related disruptions, together with provide chain constraints being skilled broadly throughout all industries. Clearly, we understand the significance {that a} differentiated digital robotic platform can have for affected person outcomes and the market. We proceed to spend money on and be dedicated to the platform and we’ll present updates to the exterior group as warranted.”
This information means Medtronic continues to drag forward of J&J in terms of taking up Intuitive Surgical, the house’s dominant participant with its da Vinci robots. Medtronic’s Hugo platform acquired European approval final week.
J&J EVP Ashley McEvoy additionally touched on the Ottava setbacks through the name. She mentioned that whereas transformational innovation “is every kind of enjoyable,” the complexities can result in technical challenges.
“We’re completely dedicated to resolving our challenges, persevering with to take a position and bringing to market a aggressive, differentiated providing as quickly as potential,” McEvoy mentioned on Ottava.
In the course of the firm’s medical machine replace in November 2020, J&J unveiled the system and it touted as able to providing unmatched flexibility and management in comparison with the remainder of the market. The time period “Ottava,” in Italian, means to play music an octave greater, highlighting the corporate’s goal to proverbially go an octave greater in medical intervention, in response to J&J’s robotics chief growth officer Dr. Frederic Moll, an Intuitive Surgical co-founder who joined J&J via its acquisition of his Auris Well being in 2019.
J&J designed Ottava with six arms to offer extra management and adaptability in surgical procedure, whereas its arms will likely be built-in into the working desk. Moreover, on the time of unveiling, the corporate mentioned the platform has a zero-footprint design to allow affected person entry, enhance house within the working room and enhance workflow.
Robotic-assisted surgical procedure stays a scorching space in medtech — with Medtronic, J&J and a number of smaller corporations searching for to compete towards Intuitive.
Adam Sachs, CEO and founding father of Vicarious Surgical, was lately a visitor on The Robotic Report Podcast. Vicarious is growing a robot-assisted surgical system that in 2019 gained FDA breakthrough machine designation for its digital reality-based robot-assisted surgical machine. He mentioned the challenges and keys to growing the system, the alternatives forward, and debuting on the NYSE by way of SPAC. You possibly can take heed to that interview under.
Editor’s Observe: This text first appeared on sister web site MassDevice.
[ad_2]